Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SBRT-IL2
- 18 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 28 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2018, according to ClinicalTrials.gov record.